KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Total Debt (2023 - 2025)

Biocryst Pharmaceuticals (BCRX) has disclosed Total Debt for 8 consecutive years, with $38.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Debt fell 88.94% year-over-year to $38.5 million, compared with a TTM value of $38.5 million through Dec 2025, down 88.94%, and an annual FY2025 reading of $38.5 million, down 88.94% over the prior year.
  • Total Debt was $38.5 million for Q4 2025 at Biocryst Pharmaceuticals, down from $232.1 million in the prior quarter.
  • Across five years, Total Debt topped out at $349.7 million in Q1 2025 and bottomed at $38.5 million in Q4 2025.
  • Average Total Debt over 3 years is $285.1 million, with a median of $312.4 million recorded in 2023.
  • The sharpest move saw Total Debt soared 43.86% in 2024, then crashed 88.94% in 2025.
  • Year by year, Total Debt stood at $326.8 million in 2023, then increased by 6.35% to $347.5 million in 2024, then plummeted by 88.94% to $38.5 million in 2025.
  • Business Quant data shows Total Debt for BCRX at $38.5 million in Q4 2025, $232.1 million in Q3 2025, and $278.5 million in Q2 2025.